Submitted by Anonymous (not verified) on 17 September 2026 - 12:25
Human medicines European public assessment report (EPAR): Qinlock, ripretinib, Date of authorisation: 18/11/2021, Revision: 11, Status: Authorised
Source:
Human medicines European public assessment report (EPAR): Qinlock, ripretinib, Date of authorisation: 18/11/2021, Revision: 11, Status: Authorised